COLORADO SPRINGS, Colo., July 27, 2011 /PRNewswire/ -- Stryker Neurovascular, a division of Stryker Corporation, today announced the results of its Matrix and Platinum Science (MAPS) Trial during the Society of NeuroInterventional Surgery (SNIS) 8th Annual Meeting in Colorado Springs. The MAPS Trial establishes a new standard for the measurement of aneurysm treatment success, target aneurysm recurrence rate (TAR)*, and proves that coiling is an excellent treatment for both ruptured and unruptured aneurysms.
Begun in 2007, the MAPS trial is the largest, most rigorous randomized controlled study to-date on the clinical effectiveness of coils for treating both ruptured and unruptured aneurysms, which are estimated to affect approximately 5% of the population. Designed and led by Principal Investigators S. Claiborne Johnston, M.D., Ph.D., Cameron McDougall, M.D., and Anil Gholkar, O.B.E., M.B.B.S., the trial examined 626 patients worldwide with a single aneurysm, 4-20mm in size, treated with Matrix(2)® Detachable Coils or GDC® Detachable Coils.
Implanted in more than 250,000 patients worldwide, GDC Detachable Coils are made of very soft platinum wire and were the first coils cleared by the FDA for the minimally invasive treatment of brain aneurysms in 1995. Cleared in 2002, Matrix(2) Detachable Coils incorporate a PGLA polymer on the outside of a traditional platinum coil that is designed to degrade over time and promote rapid tissue development within the aneurysm.
"While the neurovascular specialty commonly measures aneurysm treatment success with angiographic images, we believe success should be more closely aligned with patients' clinical outcomes," said Mark Paul, president of Stryker Neurovascular. "The MAPS Trial demonstrates the validity of TAR as a clinical endpoint and proves aneurysm coiling is a very effective therapy with excellent clinical outcomes."
In the trial, 96% of patients with unruptured aneurysm
Copyright©2010 PR Newswire.
All rights reserved